25 XP   0   0   10

Summit Therapeutics PLC
Buy, Hold or Sell?

Let's analyze Summit Therapeutics PLC together

I guess you are interested in Summit Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Summit Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Summit Therapeutics PLC

I send you an email if I find something interesting about Summit Therapeutics PLC.

Quick analysis of Summit Therapeutics PLC (30 sec.)










What can you expect buying and holding a share of Summit Therapeutics PLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.06
Expected worth in 1 year
$-0.06
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.13
Return On Investment
-1.8%

For what price can you sell your share?

Current Price per Share
$6.89
Expected price per share
$2.93 - $11.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Summit Therapeutics PLC (5 min.)




Live pricePrice per Share (EOD)

$6.89

Intrinsic Value Per Share

$-1.34 - $-1.13

Total Value Per Share

$-1.28 - $-1.06

2. Growth of Summit Therapeutics PLC (5 min.)




Is Summit Therapeutics PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$44.2m$111.1m-$25.9m-30.5%

How much money is Summit Therapeutics PLC making?

Current yearPrevious yearGrowGrow %
Making money-$29m-$410.9m$381.9m1,316.7%
Net Profit Margin2,324.5%-584,054.0%--

How much money comes from the company's main activities?

3. Financial Health of Summit Therapeutics PLC (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Summit Therapeutics PLC? (5 min.)

Welcome investor! Summit Therapeutics PLC's management wants to use your money to grow the business. In return you get a share of Summit Therapeutics PLC.

What can you expect buying and holding a share of Summit Therapeutics PLC?

First you should know what it really means to hold a share of Summit Therapeutics PLC. And how you can make/lose money.

Speculation

The Price per Share of Summit Therapeutics PLC is $6.89. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Summit Therapeutics PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Summit Therapeutics PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.06. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Summit Therapeutics PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.06-0.9%-0.04-0.6%-0.02-0.4%-0.03-0.4%-0.02-0.3%
Usd Book Value Change Per Share-0.05-0.7%-0.03-0.5%0.020.4%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-0.7%-0.03-0.5%0.020.4%0.000.0%0.000.0%
Usd Price Per Share3.93-2.97-1.74-3.18-5.36-
Price to Earnings Ratio-15.86--18.93--19.08--33.17--104.95-
Price-to-Total Gains Ratio-82.40--95.70--71.76--93.75--224.33-
Price to Book Ratio62.40-30.96-11.54-33.52-265.22-
Price-to-Total Gains Ratio-82.40--95.70--71.76--93.75--224.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.89
Number of shares145
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.00
Usd Total Gains Per Share-0.030.00
Gains per Quarter (145 shares)-4.61-0.06
Gains per Year (145 shares)-18.44-0.24
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-18-280-0-10
20-37-460-0-10
30-55-640-1-10
40-74-820-1-10
50-92-1000-1-10
60-111-1180-1-10
70-129-1360-2-10
80-148-1540-2-10
90-166-1720-2-10
100-184-1900-2-10

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%2.049.00.03.9%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%5.014.01.025.0%13.026.01.032.5%21.028.02.041.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.051.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%5.014.01.025.0%13.026.01.032.5%21.028.02.041.2%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Summit Therapeutics PLC

About Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Fundamental data was last updated by Penke on 2024-06-15 23:12:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Summit Therapeutics PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Summit Therapeutics PLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Summit Therapeutics PLC to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Summit Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2,324.5%-2,324.5%
TTM2,324.5%YOY-584,054.0%+586,378.5%
TTM2,324.5%5Y-126,023.7%+128,348.2%
5Y-126,023.7%10Y-65,327.3%-60,696.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.0%+168.0%
TTM2,324.5%-209.9%+2,534.4%
YOY-584,054.0%-242.3%-583,811.7%
5Y-126,023.7%-401.7%-125,622.0%
10Y-65,327.3%-532.2%-64,795.1%
1.1.2. Return on Assets

Shows how efficient Summit Therapeutics PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Summit Therapeutics PLC to the Biotechnology industry mean.
  • -24.6% Return on Assets means that Summit Therapeutics PLC generated $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Summit Therapeutics PLC:

  • The MRQ is -24.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.6%TTM-14.6%-10.0%
TTM-14.6%YOY-165.3%+150.6%
TTM-14.6%5Y-47.2%+32.5%
5Y-47.2%10Y-28.8%-18.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.6%-11.9%-12.7%
TTM-14.6%-11.9%-2.7%
YOY-165.3%-11.3%-154.0%
5Y-47.2%-13.5%-33.7%
10Y-28.8%-14.9%-13.9%
1.1.3. Return on Equity

Shows how efficient Summit Therapeutics PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Summit Therapeutics PLC to the Biotechnology industry mean.
  • -98.3% Return on Equity means Summit Therapeutics PLC generated $-0.98 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Summit Therapeutics PLC:

  • The MRQ is -98.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -44.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-98.3%TTM-44.8%-53.6%
TTM-44.8%YOY-314.3%+269.5%
TTM-44.8%5Y-87.6%+42.8%
5Y-87.6%10Y-57.3%-30.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-98.3%-14.2%-84.1%
TTM-44.8%-15.7%-29.1%
YOY-314.3%-14.3%-300.0%
5Y-87.6%-19.2%-68.4%
10Y-57.3%-19.7%-37.6%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Summit Therapeutics PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Summit Therapeutics PLC is operating .

  • Measures how much profit Summit Therapeutics PLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Summit Therapeutics PLC to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Summit Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2,279.4%-2,279.4%
TTM2,279.4%YOY-723,097.9%+725,377.3%
TTM2,279.4%5Y-153,324.6%+155,604.0%
5Y-153,324.6%10Y-79,390.5%-73,934.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--354.6%+354.6%
TTM2,279.4%-225.9%+2,505.3%
YOY-723,097.9%-252.2%-722,845.7%
5Y-153,324.6%-428.3%-152,896.3%
10Y-79,390.5%-531.1%-78,859.4%
1.2.2. Operating Ratio

Measures how efficient Summit Therapeutics PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Summit Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-21.899+21.899
TTM-21.899YOY4,424.741-4,446.640
TTM-21.8995Y977.536-999.435
5Y977.53610Y29,145,206,605.946-29,145,205,628.410
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM-21.8993.332-25.231
YOY4,424.7413.502+4,421.239
5Y977.5365.271+972.265
10Y29,145,206,605.9466.915+29,145,206,599.031
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Summit Therapeutics PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Summit Therapeutics PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.97 means the company has $6.97 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Summit Therapeutics PLC:

  • The MRQ is 6.966. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.283. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.966TTM9.283-2.317
TTM9.283YOY11.151-1.868
TTM9.2835Y6.301+2.982
5Y6.30110Y5.484+0.817
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.9663.767+3.199
TTM9.2834.000+5.283
YOY11.1514.905+6.246
5Y6.3015.883+0.418
10Y5.4846.286-0.802
1.3.2. Quick Ratio

Measures if Summit Therapeutics PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Summit Therapeutics PLC to the Biotechnology industry mean.
  • A Quick Ratio of 10.79 means the company can pay off $10.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Summit Therapeutics PLC:

  • The MRQ is 10.795. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.446. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.795TTM15.446-4.652
TTM15.446YOY12.594+2.853
TTM15.4465Y7.812+7.634
5Y7.81210Y6.029+1.783
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.7953.054+7.741
TTM15.4463.506+11.940
YOY12.5944.756+7.838
5Y7.8125.757+2.055
10Y6.0296.338-0.309
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Summit Therapeutics PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Summit Therapeutics PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Summit Therapeutics PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.75 means that Summit Therapeutics PLC assets are financed with 75.0% credit (debt) and the remaining percentage (100% - 75.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Summit Therapeutics PLC:

  • The MRQ is 0.750. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.602. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.750TTM0.602+0.148
TTM0.602YOY0.473+0.129
TTM0.6025Y0.395+0.207
5Y0.39510Y0.434-0.039
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7500.330+0.420
TTM0.6020.342+0.260
YOY0.4730.287+0.186
5Y0.3950.368+0.027
10Y0.4340.382+0.052
1.4.2. Debt to Equity Ratio

Measures if Summit Therapeutics PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Summit Therapeutics PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 299.9% means that company has $3.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Summit Therapeutics PLC:

  • The MRQ is 2.999. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.699. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.999TTM1.699+1.300
TTM1.699YOY1.546+0.152
TTM1.6995Y0.923+0.776
5Y0.92310Y2.199-1.277
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9990.365+2.634
TTM1.6990.415+1.284
YOY1.5460.370+1.176
5Y0.9230.443+0.480
10Y2.1990.476+1.723
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Summit Therapeutics PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Summit Therapeutics PLC generates.

  • Above 15 is considered overpriced but always compare Summit Therapeutics PLC to the Biotechnology industry mean.
  • A PE ratio of -15.86 means the investor is paying $-15.86 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Summit Therapeutics PLC:

  • The EOD is -27.814. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.865. Based on the earnings, the company is expensive. -2
  • The TTM is -18.932. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-27.814MRQ-15.865-11.949
MRQ-15.865TTM-18.932+3.067
TTM-18.932YOY-19.077+0.145
TTM-18.9325Y-33.167+14.235
5Y-33.16710Y-104.951+71.784
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-27.814-2.341-25.473
MRQ-15.865-2.997-12.868
TTM-18.932-2.882-16.050
YOY-19.077-3.553-15.524
5Y-33.167-6.262-26.905
10Y-104.951-6.288-98.663
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Summit Therapeutics PLC:

  • The EOD is -40.121. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.885. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -23.397. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-40.121MRQ-22.885-17.236
MRQ-22.885TTM-23.397+0.513
TTM-23.397YOY12.914-36.311
TTM-23.3975Y-31.031+7.634
5Y-31.03110Y-90.481+59.450
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-40.121-2.932-37.189
MRQ-22.885-3.739-19.146
TTM-23.397-3.776-19.621
YOY12.914-4.917+17.831
5Y-31.031-7.942-23.089
10Y-90.481-8.503-81.978
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Summit Therapeutics PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 62.40 means the investor is paying $62.40 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Summit Therapeutics PLC:

  • The EOD is 109.402. Based on the equity, the company is expensive. -2
  • The MRQ is 62.402. Based on the equity, the company is expensive. -2
  • The TTM is 30.962. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD109.402MRQ62.402+47.000
MRQ62.402TTM30.962+31.439
TTM30.962YOY11.544+19.418
TTM30.9625Y33.524-2.561
5Y33.52410Y265.223-231.699
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD109.4021.843+107.559
MRQ62.4022.249+60.153
TTM30.9622.301+28.661
YOY11.5442.412+9.132
5Y33.5243.782+29.742
10Y265.2234.212+261.011
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Summit Therapeutics PLC.

3.1. Institutions holding Summit Therapeutics PLC

Institutions are holding 7.228% of the shares of Summit Therapeutics PLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc1.39030.000797593837824648.7164
2024-03-31Vanguard Group Inc1.03550.000672692432542613.6245
2023-12-31Geode Capital Management, LLC0.43960.000830856661286034.349
2023-12-31State Street Corporation0.34990.000324561681895998.365
2023-12-31Northern Trust Corp0.15790.00051108089395903.7052
2024-03-31Charles Schwab Investment Management Inc0.14480.0011016545626996.5733
2023-12-31Morgan Stanley - Brokerage Accounts0.10030.000270427214893626.8191
2024-03-31Rafferty Asset Management, LLC0.09260.016502866502860
2023-12-31Steward Partners Investment Advisory, LLC0.08550.0212600000-50000-7.6923
2023-12-31Nuveen Asset Management, LLC0.08060.000556562417587745.1259
2024-03-31Citigroup Inc0.07960.00155590065298691818.5434
2024-03-31Federated Hermes Inc0.07860.00535517695394534380.0991
2024-03-31ALPS Advisors Inc0.07050.0145494924-37482-7.0401
2023-12-31Goldman Sachs Group Inc0.05540.0001388816196618102.2997
2023-12-31Bank of New York Mellon Corp0.04880.0002342529241997.6019
2023-12-31Barclays PLC0.04540.0003318565170549115.2234
2024-03-31Sectoral Asset Management Inc0.04490.5127315000285000950
2023-12-31JPMorgan Chase & Co0.04220.00012962058239138.534
2024-03-31Swiss National Bank0.03920.000827500000
2023-12-31Susquehanna International Group, LLP0.03280.000123035010397982.2807
Total 4.41440.571430987440+4276891+13.8%

3.2. Funds holding Summit Therapeutics PLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-05-30SPDR® S&P Biotech ETF0.7550.85675299975-6956-0.1311
2024-04-30Fidelity Select Biotechnology0.62030.3954435432900
2024-04-30Vanguard Total Stock Mkt Idx Inv0.51160.00093591598-75672-2.0634
2024-05-29iShares Russell 2000 ETF0.37950.01352663756-29696-1.1025
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr0.26820.00751882444-408-0.0217
2024-03-31Fidelity Small Cap Index0.16330.01771146546-38647-3.2608
2024-04-30Fidelity Select Health Care0.15670.0583110000010000010
2024-05-29iShares Russell 2000 Growth ETF0.13850.026397228800
2024-04-30Fidelity Advisor Health Care I0.10680.06375000015000025
2024-04-30Fidelity Growth Compy Commingled Pl O0.10270.0037720721292214.2257
2024-04-30State St Russell Sm/Mid Cp® Indx NL Cl C0.10160.00771348500
2024-04-30Fidelity Extended Market Index0.10160.0077713179-6463-0.8981
2024-05-29iShares Biotechnology ETF0.08550.025160021096051.6263
2024-05-30Schwab US Small-Cap ETF™0.0850.010659649600
2024-04-30Fidelity Growth Company Fund0.07740.0037543457169583.2209
2024-05-29Direxion Daily S&P Biotech Bull 3X ETF0.07530.147652862680361.5436
2024-05-30ALPS Medical Breakthroughs ETF0.07195.14450499443000.8588
2024-04-30Vanguard Health Care ETF0.06730.0093472726-1064-0.2246
2024-04-30Vanguard Russell 2000 ETF0.06160.017943271014540.3372
2024-04-30State St Russell Sm Cap® Indx SL Cl I0.06020.018442270000
Total 3.996.834328010240+160668+0.6%

3.3. Insider Transactions

Insiders are holding 88.144% of the shares of Summit Therapeutics PLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-26Ankur DhingraBUY1000003.75
2024-03-26Mahkam ZanganehBUY300003.75
2023-12-13Ankur DhingraBUY204002.17
2023-12-12Mahkam ZanganehBUY50002.07
2023-10-13Manmeet Singh SoniBUY29761901.68
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Summit Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.048-0.032-33%0.025-294%0.000-99%0.001-8493%
Book Value Per Share--0.0630.121-48%0.158-60%0.111-43%0.073-14%
Current Ratio--6.9669.283-25%11.151-38%6.301+11%5.484+27%
Debt To Asset Ratio--0.7500.602+25%0.473+59%0.395+90%0.434+73%
Debt To Equity Ratio--2.9991.699+77%1.546+94%0.923+225%2.199+36%
Dividend Per Share----0%-0%-0%-0%
Eps---0.062-0.041-33%-0.025-60%-0.027-57%-0.017-72%
Free Cash Flow Per Share---0.043-0.033-22%-0.012-71%-0.022-50%-0.013-69%
Free Cash Flow To Equity Per Share---0.042-0.031-27%0.228-119%0.035-221%0.017-348%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.126--------
Intrinsic Value_10Y_min---1.342--------
Intrinsic Value_1Y_max---0.062--------
Intrinsic Value_1Y_min---0.103--------
Intrinsic Value_3Y_max---0.225--------
Intrinsic Value_3Y_min---0.337--------
Intrinsic Value_5Y_max---0.435--------
Intrinsic Value_5Y_min---0.603--------
Market Cap4836642420.480+43%2758781525.7602086635645.120+32%1223200205.760+126%2232626432.375+24%3763200879.797-27%
Net Profit Margin---23.245-100%-5840.5400%-1260.2370%-653.2730%
Operating Margin---22.794-100%-7230.9790%-1533.2460%-793.9050%
Operating Ratio----21.8990%4424.741-100%977.536-100%29145206605.946-100%
Pb Ratio109.402+43%62.40230.962+102%11.544+441%33.524+86%265.223-76%
Pe Ratio-27.814-75%-15.865-18.932+19%-19.077+20%-33.167+109%-104.951+562%
Price Per Share6.890+43%3.9302.973+32%1.743+126%3.180+24%5.361-27%
Price To Free Cash Flow Ratio-40.121-75%-22.885-23.397+2%12.914-277%-31.031+36%-90.481+295%
Price To Total Gains Ratio-144.455-75%-82.396-95.704+16%-71.760-13%-93.753+14%-224.327+172%
Quick Ratio--10.79515.446-30%12.594-14%7.812+38%6.029+79%
Return On Assets---0.246-0.146-40%-1.653+572%-0.472+92%-0.288+17%
Return On Equity---0.983-0.448-54%-3.143+220%-0.876-11%-0.573-42%
Total Gains Per Share---0.048-0.032-33%0.025-294%0.000-99%0.001-8493%
Usd Book Value--44210000.00085220000.000-48%111175250.000-60%78121363.500-43%51464849.284-14%
Usd Book Value Change Per Share---0.048-0.032-33%0.025-294%0.000-99%0.001-8493%
Usd Book Value Per Share--0.0630.121-48%0.158-60%0.111-43%0.073-14%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.062-0.041-33%-0.025-60%-0.027-57%-0.017-72%
Usd Free Cash Flow---30138000.000-23460500.000-22%-8760906.000-71%-15181844.162-50%-9390165.435-69%
Usd Free Cash Flow Per Share---0.043-0.033-22%-0.012-71%-0.022-50%-0.013-69%
Usd Free Cash Flow To Equity Per Share---0.042-0.031-27%0.228-119%0.035-221%0.017-348%
Usd Market Cap4836642420.480+43%2758781525.7602086635645.120+32%1223200205.760+126%2232626432.375+24%3763200879.797-27%
Usd Price Per Share6.890+43%3.9302.973+32%1.743+126%3.180+24%5.361-27%
Usd Profit---43473000.000-29006250.000-33%-410932750.000+845%-97868272.211+125%-50777243.333+17%
Usd Revenue----0%113926.250-100%177831.300-100%2525733.200-100%
Usd Total Gains Per Share---0.048-0.032-33%0.025-294%0.000-99%0.001-8493%
 EOD+5 -3MRQTTM+4 -27YOY+8 -235Y+9 -2210Y+8 -23

4.2. Fundamental Score

Let's check the fundamental score of Summit Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-27.814
Price to Book Ratio (EOD)Between0-1109.402
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.795
Current Ratio (MRQ)Greater than16.966
Debt to Asset Ratio (MRQ)Less than10.750
Debt to Equity Ratio (MRQ)Less than12.999
Return on Equity (MRQ)Greater than0.15-0.983
Return on Assets (MRQ)Greater than0.05-0.246
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Summit Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.933
Ma 20Greater thanMa 507.887
Ma 50Greater thanMa 1006.052
Ma 100Greater thanMa 2005.094
OpenGreater thanClose7.700
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2024-04-30. Currency in USD. All numbers in thousands.

Summary
Total Assets176,781
Total Liabilities132,571
Total Stockholder Equity44,210
 As reported
Total Liabilities 132,571
Total Stockholder Equity+ 44,210
Total Assets = 176,781

Assets

Total Assets176,781
Total Current Assets163,265
Long-term Assets13,516
Total Current Assets
Cash And Cash Equivalents 61,294
Short-term Investments 95,386
Net Receivables 945
Inventory 317
Other Current Assets 5,323
Total Current Assets  (as reported)163,265
Total Current Assets  (calculated)163,265
+/-0
Long-term Assets
Property Plant Equipment 9,554
Goodwill 1,875
Long-term Assets Other 2,087
Long-term Assets  (as reported)13,516
Long-term Assets  (calculated)13,516
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities23,438
Long-term Liabilities109,133
Total Stockholder Equity44,210
Total Current Liabilities
Short-term Debt 3,699
Accounts payable 6,371
Other Current Liabilities 788
Total Current Liabilities  (as reported)23,438
Total Current Liabilities  (calculated)10,858
+/- 12,580
Long-term Liabilities
Long-term Liabilities  (as reported)109,133
Long-term Liabilities  (calculated)0
+/- 109,133
Total Stockholder Equity
Common Stock7,020
Retained Earnings -1,036,731
Accumulated Other Comprehensive Income -2,449
Other Stockholders Equity 1,076,370
Total Stockholder Equity (as reported)44,210
Total Stockholder Equity (calculated)44,210
+/-0
Other
Cash and Short Term Investments 156,680
Common Stock Shares Outstanding 701,785
Current Deferred Revenue12,580
Liabilities and Stockholders Equity 176,781
Net Debt 48,228
Short Long Term Debt Total 109,522



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-04-302024-01-312023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-312018-04-302018-01-312017-10-312017-07-312017-04-302017-01-312016-10-312016-07-312016-04-302016-01-312015-10-312015-07-312015-04-302015-01-312014-10-312014-07-312014-04-302014-01-312013-10-312013-07-312013-04-302013-01-312012-10-312012-07-312012-04-302012-01-312011-10-312011-07-312011-01-312010-07-312010-01-312009-07-312009-01-312008-07-312008-01-312007-07-312007-01-312006-07-312006-01-312005-07-312005-01-312004-07-31
> Total Assets 
180
26,878
25,481
25,868
42,980
46,441
79,668
69,381
62,487
20,095
14,729
18,379
14,855
8,057
9,182
3,896
6,118
5,464
8,584
4,377
6,913
6,713
10,230
0
10,938
34,103
39,562
34,103
52,426
29,224
52,426
45,423
19,331
35,713
19,331
52,451
46,982
39,961
54,095
64,304
76,381
87,765
61,436
56,966
78,388
69,378
58,884
50,762
72,657
70,949
56,865
56,865
102,498
140,794
145,517
128,673
113,374
116,472
95,718
155,327
664,168
254,897
237,372
218,476
202,949
176,781
176,781202,949218,476237,372254,897664,168155,32795,718116,472113,374128,673145,517140,794102,49856,86556,86570,94972,65750,76258,88469,37878,38856,96661,43687,76576,38164,30454,09539,96146,98252,45119,33135,71319,33145,42352,42629,22452,42634,10339,56234,10310,938010,2306,7136,9134,3778,5845,4646,1183,8969,1828,05714,85518,37914,72920,09562,48769,38179,66846,44142,98025,86825,48126,878180
   > Total Current Assets 
180
26,838
23,421
23,567
39,419
38,434
35,488
25,304
21,717
7,795
6,068
10,598
7,598
5,904
7,071
2,643
4,150
5,141
8,076
4,183
6,607
6,509
9,919
0
5,105
2,030
33,584
27,387
45,870
22,893
45,870
38,907
13,745
29,703
13,745
47,260
41,670
34,055
47,979
58,150
50,801
63,231
43,640
40,103
61,293
51,789
42,506
33,823
60,110
55,552
42,077
21,270
66,417
125,217
121,482
102,210
97,312
99,435
79,398
137,119
656,712
248,027
227,501
204,951
189,712
163,265
163,265189,712204,951227,501248,027656,712137,11979,39899,43597,312102,210121,482125,21766,41721,27042,07755,55260,11033,82342,50651,78961,29340,10343,64063,23150,80158,15047,97934,05541,67047,26013,74529,70313,74538,90745,87022,89345,87027,38733,5842,0305,10509,9196,5096,6074,1838,0765,1414,1502,6437,0715,9047,59810,5986,0687,79521,71725,30435,48838,43439,41923,56723,42126,838180
       Cash And Cash Equivalents 
177
26,663
22,667
1,857
37,766
35,874
28,913
20,060
15,856
3,916
1,438
9,717
7,133
5,143
6,044
2,076
3,260
4,754
7,469
3,379
5,337
6,004
9,150
0
3,349
24,015
29,489
24,015
41,244
16,973
41,244
34,237
9,244
23,220
9,244
42,289
35,076
25,036
37,184
42,028
28,454
38,119
22,498
16,576
35,226
36,614
25,374
17,547
48,194
36,410
21,270
21,270
66,417
102,194
103,386
80,248
71,791
77,450
57,335
121,971
348,607
70,969
42,116
23,792
71,425
61,294
61,29471,42523,79242,11670,969348,607121,97157,33577,45071,79180,248103,386102,19466,41721,27021,27036,41048,19417,54725,37436,61435,22616,57622,49838,11928,45442,02837,18425,03635,07642,2899,24423,2209,24434,23741,24416,97341,24424,01529,48924,0153,34909,1506,0045,3373,3797,4694,7543,2602,0766,0445,1437,1339,7171,4383,91615,85620,06028,91335,87437,7661,85722,66726,663177
       Short-term Investments 
0
0
0
20,697
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
170,963
170,963
172,898
175,153
114,817
95,386
95,386114,817175,153172,898170,963170,9630000000000000000000000000000000000000000000000000000000020,697000
       Net Receivables 
0
0
0
0
1,287
0
3,757
0
2,602
0
2,770
0
0
0
0
0
0
0
0
0
0
0
770
0
720
4,095
4,095
3,372
5,667
3,372
1,741
2,907
5,775
2,907
2,672
3,623
3,623
7,068
8,983
11,078
11,078
7,802
6,042
7,241
7,241
2,944
17,132
16,275
18,137
17,882
11,999
11,999
10,187
14,043
11,406
12,362
17,159
16,160
14,370
13,098
6,115
5,686
4,607
812
848
945
9458488124,6075,6866,11513,09814,37016,16017,15912,36211,40614,04310,18711,99911,99917,88218,13716,27517,1322,9447,2417,2416,0427,80211,07811,0788,9837,0683,6233,6232,6722,9075,7752,9071,7413,3725,6673,3724,0954,0957200770000000000002,77002,60203,75701,2870000
       Other Current Assets 
4
0
754
0
312
0
2,261
0
2,257
0
1,480
0
203
0
222
0
0
0
333
0
354
0
0
0
568
0
0
0
0
0
2,885
1,764
2,987
1,764
1,829
1,348
1,348
1,951
1,811
5,044
5,044
17,310
15,101
16,286
16,286
12,230
0
0
0
1,260
8,808
1,667
1,523
985
963
1,191
1,201
1,475
2,300
428
486
409
1,787
120
181
5,323
5,3231811201,7874094864282,3001,4751,2011,1919639851,5231,6678,8081,26000012,23016,28616,28615,10117,3105,0445,0441,8111,9511,3481,3481,8291,7642,9871,7642,885000005680003540333000222020301,48002,25702,2610312075404
   > Long-term Assets 
0
40
2,060
2,301
3,561
8,007
44,180
44,077
40,769
12,300
8,661
7,780
7,257
2,152
2,110
1,253
1,968
323
507
194
306
204
311
0
5,833
6,717
5,978
6,717
6,556
6,331
6,556
6,516
5,587
6,010
5,587
5,191
5,312
5,907
6,117
6,154
25,580
24,534
17,796
16,863
17,095
17,589
16,379
16,940
12,546
15,397
14,788
35,595
36,081
15,577
24,035
26,463
16,062
17,037
16,320
18,208
7,456
6,870
9,871
13,525
13,237
13,516
13,51613,23713,5259,8716,8707,45618,20816,32017,03716,06226,46324,03515,57736,08135,59514,78815,39712,54616,94016,37917,58917,09516,86317,79624,53425,5806,1546,1175,9075,3125,1915,5876,0105,5876,5166,5566,3316,5566,7175,9786,7175,83303112043061945073231,9681,2532,1102,1527,2577,7808,66112,30040,76944,07744,1808,0073,5612,3012,060400
       Property Plant Equipment 
0
2
1,998
2,251
3,453
5,147
6,972
8,487
8,247
5,353
892
535
356
411
305
149
234
154
242
23
36
38
58
0
71
78
81
78
94
83
94
128
116
118
116
139
145
610
736
749
1,145
1,042
922
801
808
1,799
1,660
1,589
1,162
1,241
1,352
1,352
1,279
2,171
2,969
2,540
3,484
3,397
3,112
5,160
5,081
4,340
7,221
6,632
6,063
9,554
9,5546,0636,6327,2214,3405,0815,1603,1123,3973,4842,5402,9692,1711,2791,3521,3521,2411,1621,5891,6601,7998088019221,0421,145749736610145139116118116128948394788178710583836232421542341493054113565358925,3538,2478,4876,9725,1473,4532,2511,99820
       Goodwill 
0
0
0
0
0
0
19,876
19,422
19,367
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,092
1,062
1,000
1,062
1,036
1,000
1,036
1,024
877
946
877
811
830
859
873
877
3,508
3,412
2,383
2,305
2,379
2,346
2,206
2,340
1,480
2,236
2,335
2,335
2,030
2,047
2,057
2,001
2,009
1,953
1,806
1,655
1,798
1,839
1,883
1,814
1,893
1,875
1,8751,8931,8141,8831,8391,7981,6551,8061,9532,0092,0012,0572,0472,0302,3352,3352,2361,4802,3402,2062,3462,3792,3052,3833,4123,5088778738598308118779468771,0241,0361,0001,0361,0621,0001,0621,09200000000000000019,36719,42219,876000000
       Intangible Assets 
0
38
61
50
108
2,860
17,332
16,169
13,155
6,947
7,769
7,245
6,901
1,741
1,805
1,104
1,734
169
265
171
270
166
253
0
5,762
5,576
5,897
5,576
5,426
5,248
5,426
5,363
4,593
4,946
4,593
4,241
4,337
4,438
4,508
4,528
20,928
20,079
14,491
13,757
13,908
13,444
12,513
13,010
9,904
11,920
11,101
11,101
11,515
11,359
11,161
10,608
10,399
9,866
8,900
7,952
0
0
0
0
0
0
0000007,9528,9009,86610,39910,60811,16111,35911,51511,10111,10111,9209,90413,01012,51313,44413,90813,75714,49120,07920,9284,5284,5084,4384,3374,2414,5934,9464,5935,3635,4265,2485,4265,5765,8975,5765,76202531662701712651691,7341,1041,8051,7416,9017,2457,7696,94713,15516,16917,3322,8601085061380
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,230
6,352
0
0
0
0
0
0
0
5,299
5,402
0
0
0
1,000,000,000,000,000
1,000,000,000,000,000
0
0
0
0
0
0
0
0
0
7,848
11,314
170
57,645
39,022
38,383
15,148
0
767
12,487
0
0
0
00012,487767015,14838,38339,02257,64517011,3147,8480000000001,000,000,000,000,0001,000,000,000,000,0000005,4025,29900000006,3526,2300000000000000000000000000000
> Total Liabilities 
213
350
975
2,492
1,771
6,328
13,877
15,302
15,199
7,767
5,321
5,154
4,585
2,236
3,415
1,285
2,340
685
1,076
1,526
2,410
1,460
2,225
0
3,083
5,851
5,747
5,851
5,283
6,675
5,283
5,445
5,366
5,616
5,366
51,122
51,348
50,279
49,495
43,028
62,404
79,815
18,022
21,341
22,592
19,407
17,898
16,109
10,393
19,003
20,004
20,004
23,045
76,389
26,090
26,375
30,090
52,065
44,401
22,079
537,514
121,415
117,773
119,097
125,257
132,571
132,571125,257119,097117,773121,415537,51422,07944,40152,06530,09026,37526,09076,38923,04520,00420,00419,00310,39316,10917,89819,40722,59221,34118,02279,81562,40443,02849,49550,27951,34851,1225,3665,6165,3665,4455,2836,6755,2835,8515,7475,8513,08302,2251,4602,4101,5261,0766852,3401,2853,4152,2364,5855,1545,3217,76715,19915,30213,8776,3281,7712,492975350213
   > Total Current Liabilities 
213
350
975
1,259
630
2,840
4,021
6,789
6,096
2,691
1,729
1,764
1,297
1,912
3,079
1,285
2,018
685
1,076
1,526
2,410
1,460
2,225
0
3,083
4,789
5,747
4,789
4,247
5,674
4,247
4,420
4,376
4,566
4,376
12,297
13,619
13,175
13,698
14,305
26,815
34,541
11,939
15,690
16,877
13,175
12,259
10,363
10,393
13,199
14,742
14,742
19,890
73,052
21,888
22,789
25,623
22,724
15,173
16,682
38,782
17,443
11,931
113,742
20,405
23,438
23,43820,405113,74211,93117,44338,78216,68215,17322,72425,62322,78921,88873,05219,89014,74214,74213,19910,39310,36312,25913,17516,87715,69011,93934,54126,81514,30513,69813,17513,61912,2974,3764,5664,3764,4204,2475,6744,2474,7895,7474,7893,08302,2251,4602,4101,5261,0766852,0181,2853,0791,9121,2971,7641,7292,6916,0966,7894,0212,8406301,259975350213
       Short-term Debt 
0
0
0
118
123
129
134
374
424
195
25
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,440
0
6,912
37
6,887
6,912
6,912
11,435
4,558
3,422
463
3,422
463
435
462
1,005
400
386
386
390
56,019
1,006
941
1,091
907
684
1,392
21,460
1,693
2,928
102,780
2,809
3,699
3,6992,809102,7802,9281,69321,4601,3926849071,0919411,00656,0193903863864001,0054624354633,4224633,4224,55811,4356,9126,9126,887376,91208,440000000000000000000000025195424374134129123118000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,883
0
0
0
0
0
0
54,963
0
0
0
0
0
0
19,770
0
0
100,000
0
0
0
000100,0000019,77000000054,9630000003,883000000000000000000000000000000000000000000000
       Accounts payable 
0
34
0
871
506
2,258
3,887
3,605
5,078
973
1,034
238
1,297
525
3,079
372
584
685
1,076
254
401
1,460
2,225
0
576
4,037
4,447
4,037
4,155
5,606
4,155
4,319
4,376
4,566
4,376
3,856
4,980
4,127
4,613
5,174
6,248
16,393
8,650
6,750
11,627
8,738
7,899
9,314
3,375
3,091
2,493
2,493
6,140
4,114
6,949
5,875
4,374
6,959
3,574
1,431
355
710
987
3,314
2,667
6,371
6,3712,6673,3149877103551,4313,5746,9594,3745,8756,9494,1146,1402,4932,4933,0913,3759,3147,8998,73811,6276,7508,65016,3936,2485,1744,6134,1274,9803,8564,3764,5664,3764,3194,1555,6064,1554,0374,4474,03757602,2251,4604012541,0766855843723,0795251,2972381,0349735,0783,6053,8872,2585068710340
       Other Current Liabilities 
213
316
975
270
0
453
0
2,810
593
1,523
670
1,526
0
1,386
0
913
1,434
0
0
1,272
2,009
0
0
0
2,507
752
1,300
752
92
68
92
102
3,531
-8,440
199
6,912
199
6,997
13,824
6,912
0
1,093
825
1,093
825
813
97
103
8,853
5,190
4,752
4,752
4,990
5,496
6,793
8,462
12,219
9,761
7,684
13,859
16,967
15,040
619
484
717
788
78871748461915,04016,96713,8597,6849,76112,2198,4626,7935,4964,9904,7524,7525,1908,853103978138251,0938251,09306,91213,8246,9971996,912199-8,4403,5311029268927521,3007522,5070002,0091,272001,43491301,38601,5266701,5235932,81004530270975316213
   > Long-term Liabilities 
0
34
0
1,234
1,142
3,488
9,856
8,513
9,104
5,076
3,592
3,390
3,289
324
336
0
322
0
1,076
0
401
0
2,225
0
576
1,062
4,447
1,062
1,036
1,000
1,036
1,024
990
1,050
990
38,825
37,729
37,104
35,797
28,723
35,589
45,274
6,083
5,651
5,714
6,231
5,639
5,746
-1,675
5,804
5,262
5,262
3,155
3,337
4,202
3,586
4,467
29,341
29,228
5,397
498,732
103,972
105,842
5,355
104,852
109,133
109,133104,8525,355105,842103,972498,7325,39729,22829,3414,4673,5864,2023,3373,1555,2625,2625,804-1,6755,7465,6396,2315,7145,6516,08345,27435,58928,72335,79737,10437,72938,8259901,0509901,0241,0361,0001,0361,0624,4471,06257602,225040101,076032203363243,2893,3903,5925,0769,1048,5139,8563,4881,1421,2340340
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
664
0
0
0
3,304
0
0
0
104
117
113
38,017
37,275
36,394
35,194
28,124
32,301
45,278
6,078
5,677
4,357
4,252
4,151
4,050
4,656
0
5,100
3,080
2,986
3,054
2,690
2,776
2,751
2,594
2,424
1,429
0
1,511
0
0
0
0
00001,51101,4292,4242,5942,7512,7762,6903,0542,9863,0805,10004,6564,0504,1514,2524,3575,6776,07845,27832,30128,12435,19436,39437,27538,0171131171040003,304000664000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
997
0
0
0
942
0
0
0
30,421
0
0
0
29,027
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000029,02700030,4210009420009970000000000000000000000000000
> Total Stockholder Equity
-33
26,527
24,505
23,376
41,209
40,113
65,792
54,079
47,287
12,327
9,408
13,225
10,270
5,820
5,767
-32,991
3,778
-28,307
7,508
-35,549
4,503
-31,518
8,005
0
7,855
28,252
33,816
28,252
47,143
22,549
47,143
39,978
13,965
30,098
13,965
1,330
-4,366
-10,317
4,600
21,276
13,978
7,950
43,414
35,625
55,796
49,971
40,987
34,653
-118,953
51,946
36,861
36,861
79,453
64,405
119,427
102,298
83,284
64,407
51,317
133,248
126,654
133,482
119,599
99,379
77,692
44,210
44,21077,69299,379119,599133,482126,654133,24851,31764,40783,284102,298119,42764,40579,45336,86136,86151,946-118,95334,65340,98749,97155,79635,62543,4147,95013,97821,2764,600-10,317-4,3661,33013,96530,09813,96539,97847,14322,54947,14328,25233,81628,2527,85508,005-31,5184,503-35,5497,508-28,3073,778-32,9915,7675,82010,27013,2259,40812,32747,28754,07965,79240,11341,20923,37624,50526,527-33
   Common Stock
2
5,895
5,493
5,589
6,954
7,301
10,100
12,746
11,099
8,067
9,740
11,039
10,847
10,967
11,648
1,874
11,182
8,788
13,806
3,541
13,881
9,711
14,799
0
16,619
657
22,755
657
956
619
956
946
813
873
813
755
772
800
814
933
1,042
1,129
1,078
1,046
2,104
2,075
1,952
2,071
507
672
672
672
826
829
974
976
980
981
981
2,013
2,110
6,976
6,976
6,978
7,017
7,020
7,0207,0176,9786,9766,9762,1102,0139819819809769748298266726726725072,0711,9522,0752,1041,0461,0781,1291,04293381480077275581387381394695661995665722,75565716,619014,7999,71113,8813,54113,8068,78811,1821,87411,64810,96710,84711,0399,7408,06711,09912,74610,1007,3016,9545,5895,4935,8952
   Retained Earnings -1,036,731-993,258-956,691-935,423-920,706-378,330-359,101-337,716-320,945-299,548-272,449-255,429-231,553-214,740-206,206-206,206-190,760-119,461-118,474-103,235-103,263-99,799-103,277-96,069-137,403-114,509-91,660-88,858-101,540-92,205-84,063-77,691-67,426-77,691-65,288-58,748-45,585-58,748-43,581-86,376-43,581-74,5300-62,829-41,229-61,743-39,090-58,276-37,095-54,749-34,865-55,157-50,911-45,936-43,904-66,566-52,836-42,328-28,348-15,934-8,109-4,258-1,989-293-87-215
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
180
20,719
19,305
19,775
38,513
40,921
71,626
69,681
78,517
57,097
66,233
46,089
45,358
45,764
49,275
32,991
47,345
28,307
51,978
35,549
52,365
31,518
58,996
0
65,766
100,727
100,727
26,834
75,207
38,630
37,041
41,702
73,410
68,708
58,182
62,519
62,519
67,038
66,988
68,673
88,096
112,468
108,096
108,524
108,524
98,972
72,322
151,057
118,953
242,034
-7,032
242,395
297,161
295,129
373,882
377,213
384,049
388,328
391,220
493,553
504,767
1,048,608
119,599
1,051,415
77,700
1,076,370
1,076,37077,7001,051,415119,5991,048,608504,767493,553391,220388,328384,049377,213373,882295,129297,161242,395-7,032242,034118,953151,05772,32298,972108,524108,524108,096112,46888,09668,67366,98867,03862,51962,51958,18268,70873,41041,70237,04138,63075,20726,834100,727100,72765,766058,99631,51852,36535,54951,97828,30747,34532,99149,27545,76445,35846,08966,23357,09778,51769,68171,62640,92138,51319,77519,30520,719180



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2024-01-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-2,050
Gross Profit-2,050-2,050
 
Operating Income (+$)
Gross Profit-2,050
Operating Expense-87,686
Operating Income-89,736-89,736
 
Operating Expense (+$)
Research Development59,471
Selling General Administrative23,741
Selling And Marketing Expenses2,050
Operating Expense87,68685,262
 
Net Interest Income (+$)
Interest Income10,403
Interest Expense-16,461
Other Finance Cost-0
Net Interest Income-6,058
 
Pretax Income (+$)
Operating Income-89,736
Net Interest Income-6,058
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-615,874436,402
EBIT - interestExpense = -106,197
-615,874
-598,467
Interest Expense16,461
Earnings Before Interest and Taxes (EBIT)-89,736-599,413
Earnings Before Interest and Taxes (EBITDA)-87,686
 
After tax Income (+$)
Income Before Tax-615,874
Tax Provision--
Net Income From Continuing Ops-614,928-615,874
Net Income-614,928
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses89,736
Total Other Income/Expenses Net-526,1386,058
 

Technical Analysis of Summit Therapeutics PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Summit Therapeutics PLC. The general trend of Summit Therapeutics PLC is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Summit Therapeutics PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Summit Therapeutics PLC.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 8.77 < 11.25.

The bearish price targets are: 5.78 > 5.39 > 2.93.

Tweet this
Summit Therapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Summit Therapeutics PLC. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Summit Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Summit Therapeutics PLC. The current macd is 0.39006673.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Summit Therapeutics PLC price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Summit Therapeutics PLC. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Summit Therapeutics PLC price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Summit Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartSummit Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Summit Therapeutics PLC. The current adx is 34.19.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Summit Therapeutics PLC shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Summit Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Summit Therapeutics PLC. The current sar is 5.50062237.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Summit Therapeutics PLC Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Summit Therapeutics PLC. The current rsi is 46.93. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Summit Therapeutics PLC Daily Relative Strength Index (RSI) ChartSummit Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Summit Therapeutics PLC. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Summit Therapeutics PLC price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Summit Therapeutics PLC Daily Stochastic Oscillator ChartSummit Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Summit Therapeutics PLC. The current cci is -308.09037377.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Summit Therapeutics PLC Daily Commodity Channel Index (CCI) ChartSummit Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Summit Therapeutics PLC. The current cmo is -22.19606857.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Summit Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartSummit Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Summit Therapeutics PLC. The current willr is -94.47236181.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Summit Therapeutics PLC Daily Williams %R ChartSummit Therapeutics PLC Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Summit Therapeutics PLC.

Summit Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Summit Therapeutics PLC. The current atr is 0.75564566.

Summit Therapeutics PLC Daily Average True Range (ATR) ChartSummit Therapeutics PLC Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Summit Therapeutics PLC. The current obv is 523,940,389.

Summit Therapeutics PLC Daily On-Balance Volume (OBV) ChartSummit Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Summit Therapeutics PLC. The current mfi is 66.06.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Summit Therapeutics PLC Daily Money Flow Index (MFI) ChartSummit Therapeutics PLC Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Summit Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-20MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Summit Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Summit Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.933
Ma 20Greater thanMa 507.887
Ma 50Greater thanMa 1006.052
Ma 100Greater thanMa 2005.094
OpenGreater thanClose7.700
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Summit Therapeutics PLC with someone you think should read this too:
  • Are you bullish or bearish on Summit Therapeutics PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Summit Therapeutics PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Summit Therapeutics PLC

I send you an email if I find something interesting about Summit Therapeutics PLC.


Stay informed about Summit Therapeutics PLC.

Receive notifications about Summit Therapeutics PLC in your mailbox!